

# Royalty Finance Tracker

Publications | [HIDE](#)

Gibson Dunn is a leader in [royalty finance](#), including royalty monetizations and synthetic royalty financing transactions. With an interdisciplinary team bringing together expertise in M&A, licensing, finance, intellectual property, FDA regulatory matters and tax matters, Gibson Dunn has extensive experience representing buyers and sellers of royalty entitlements, including academic institutions, biotechnology and pharmaceutical companies and royalty acquisition funds. This breadth of experience provides valuable insight and commercial perspective that can be critical to an efficient and successful royalty financing transaction.

The Gibson Dunn team has represented clients in royalty finance transactions with a total aggregate value of over \$10 Billion. Since 2020, Gibson Dunn has completed (representing either company/seller or fund/buyer) nearly 30% of the royalty finance transactions entered into by the most active funds in the space.

As a leading firm in the royalty finance space, we are using our resources and market knowledge to compile and curate all royalty finance transactions that have occurred since January 1, 2020. If you are aware of a transaction that is not appropriately reflected below, please email [GibsonDunnRoyaltyTracker@gibsondunn.com](mailto:GibsonDunnRoyaltyTracker@gibsondunn.com) with the applicable details.

| Date       | Company or Seller               | Fund or Buyer                               | Product Name                                                              | Aggregate Value     | Upfront Payment |
|------------|---------------------------------|---------------------------------------------|---------------------------------------------------------------------------|---------------------|-----------------|
| 12/30/2025 | Takeda                          | XOMA                                        | Osavampator<br>Volixibat<br>OHB-607 + 5<br>early-stage assets<br>REC-4881 | undisclosed         | undisclosed     |
| 12/4/2025  | Denali Therapeutics             | Royalty Pharma                              | tividenofusp alfa                                                         | \$275 million       | \$200 million   |
| 11/4/2025  | Blackstone                      | Royalty Pharma                              | AMVUTTRA                                                                  | \$310 million       | \$310 million   |
| 11/4/2025  | Ultragenyx                      | OMERS                                       | Crysvita                                                                  | \$400 million       | \$400 million   |
| 11/3/2025  | Merck                           | Blackstone                                  | sacituzumab<br>tirumotecan<br>(sac-TMT)                                   | \$700 million       | \$700 million   |
| 10/29/2025 | Savara                          | RTW Investments                             | MOLBREEVI                                                                 | \$75 million        | On Approval     |
| 10/20/2025 | Viridian                        | DRI Healthcare                              | veligrotug + VRDN-003                                                     | Up to \$300 million | \$55 million    |
| 9/2/2025   | Zenas BioPharma                 | Royalty Pharma                              | Obexelimab                                                                | Up to \$350 million | \$75 million    |
| 8/25/25    | BeOne Medicines Ltd.            | Royalty Pharma                              | IMDELLTRA® (tarlatamab-dlle)                                              | \$950 million       | \$885 million   |
| 7/31/25    | Orchestra BioMed Holdings, Inc. | Ligand Pharm<br>aceuticals and<br>Medtronic | Ligand - BACKBEAT<br>Cardiac Neuro<br>modulation                          | \$55 million        | \$40 million    |

## Related People

- [Ryan A. Murr](#)
- [Karen A. Spindler](#)
- [Branden C. Berns](#)
- [Charlotte Jacobsen](#)
- [Katlin McKelvie](#)
- [Jin Hee Kim](#)
- [Pamela Lawrence Endreny](#)

# GIBSON DUNN

|                                       |                                      |                                                                                                                                      | Therapy™<br>(primary<br>product) and<br>Virtue®<br>Sirolimus<br>AngioInfusion<br>Balloon<br>(secondary<br>product);<br>Medtronic – a<br>Medtronic<br>device<br>incorporating<br>AVIM |                 |                 |
|---------------------------------------|--------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------|-----------------|
| 6/30/2025                             | BridgeBio                            | HCRx and<br>Blue Owl<br>Capital                                                                                                      | BEYONTTRA<br>(acoramidis)                                                                                                                                                            | \$300 million   | \$300 million   |
| 6/25/2025                             | Ovid<br>Therapeutics                 | Immedica<br>Pharma                                                                                                                   | ganaxolone                                                                                                                                                                           | \$7 million     | \$7 million     |
| 6/24/2025                             | Revolution<br>Medicines              | Royalty<br>Pharma                                                                                                                    | daraxonrasib                                                                                                                                                                         | \$1.25 billion  | \$250 million   |
| 6/9/2025                              | MacroGenics,<br>Inc.                 | Sagard<br>Healthcare<br>Partners                                                                                                     | ZYNYZ (retifanlimab-dlwr)                                                                                                                                                            | \$70 million    | \$70 million    |
| 5/27/2025                             | BioInvent<br>International           | Xoma Royalty                                                                                                                         | mezagitamab                                                                                                                                                                          | \$30 million    | \$20 million    |
| 5/19/2025                             | RegenXBio                            | HCRx                                                                                                                                 | Zolgensma +<br>gene therapy<br>pipeline                                                                                                                                              | \$250 million   | \$150 million   |
| 5/5/2025                              | Elanco                               | Blackstone                                                                                                                           | XDEMVI                                                                                                                                                                               | \$295 million   | \$295 million   |
| 3/31/2025                             | Eagle Pharma<br>ceuticals, Inc.      | Blue Owl<br>Capital Inc.                                                                                                             | BENDEKA<br>(bendamustine<br>hydrochloride<br>injection)                                                                                                                              | \$69 million    | \$69 million    |
| 3/18/2025<br>(originally<br>1/9/2023) | Liquidia<br>Corporation              | HCRx                                                                                                                                 | YUTREPIA™<br>(treprostinil)                                                                                                                                                          | \$75 million    | \$25 million    |
| 3/17/2025                             | SWK Holdings<br>Corporation          | Soleus Capital<br>LLC                                                                                                                | Undisclosed                                                                                                                                                                          | \$34 million    | \$34 million    |
| 3/17/2025                             | SWK Funding<br>LLC                   | ANI Pharmace<br>uticals, Inc.                                                                                                        | ILUVIEN /<br>YUTIQ                                                                                                                                                                   | \$17.25 million | \$17.25 million |
| 3/12/2025<br>(originally<br>3/4/2024) | Heidelberg<br>Pharma AG              | HCRx                                                                                                                                 | Zircaix<br>(TLX250-CDx)                                                                                                                                                              | \$0             | \$20 million    |
| 3/3/2025                              | Nuvation Bio                         | Sagard<br>Healthcare<br>Partners                                                                                                     | taletrectinib                                                                                                                                                                        | \$150 million   | \$150 million   |
| 2/25/2025                             | Castle Creek<br>Biosciences,<br>Inc. | Ligand Pharm<br>aceuticals<br>(syndicate<br>includes Xoma<br>Royalty,<br>Paragon<br>Biosciences,<br>and Valor<br>Equity<br>Partners) | D-Fi<br>(FCX-007)                                                                                                                                                                    | \$75 million    | \$75 million    |
| 2/12/2025                             | Biogen                               | Royalty<br>Pharma plc                                                                                                                | litifilimab                                                                                                                                                                          | \$250 million   | Undisclosed     |

# GIBSON DUNN

|             |                                         |                          |                                                                                                                                      |                            |                            |
|-------------|-----------------------------------------|--------------------------|--------------------------------------------------------------------------------------------------------------------------------------|----------------------------|----------------------------|
| 1/30/2025   | GENFIT                                  | HCRx                     | Iqirvo®<br>(elafibranor)                                                                                                             | \$192.25<br>million        | \$135.10<br>million        |
| <b>Date</b> | <b>Company or<br/>Seller</b>            | <b>Fund or<br/>Buyer</b> | <b>Product<br/>Name</b>                                                                                                              | <b>Aggregate<br/>Value</b> | <b>Upfront<br/>Payment</b> |
| 12/2/2024   | Pulmokin Inc.                           | XOMA Royalty             | Seralutinib                                                                                                                          | \$20,000,000               | \$20,000,000               |
| 11/4/2024   | KalVista Phar<br>maceuticals            | DRI Capital              | Sebetralstat                                                                                                                         | \$179,000,000              | \$100,000,000              |
| 11/4/2024   | Syndax Pharm<br>aceuticals, Inc.        | Royalty<br>Pharma        | Niktimvo (axati<br>limab-csfr)                                                                                                       | \$350,000,000              | \$350,000,000              |
| 11/1/2024   | Geron<br>Corporation                    | Royalty<br>Pharma        | RYTELO<br>(imetelstat)                                                                                                               | \$125,000,000              | \$125,000,000              |
| 10/21/2024  | Twist<br>Bioscience<br>Corporation      | XOMA Royalty             | Various early-<br>stage<br>programs<br>(60+) across<br>Twist's<br>Biopharma<br>Solutions<br>business unit                            | \$15,000,000               | \$15,000,000               |
| 10/3/2024   | Editas<br>Medicine, Inc.                | DRI Capital              | CASGEVY                                                                                                                              | \$57,000,000               | \$57,000,000               |
| 9/20/2024   | BRAIN Biotech<br>AG                     | Royalty<br>Pharma        | Deucrichtibant                                                                                                                       | \$140,000,000              | \$20,000,000               |
| 9/3/2024    | Ascendis<br>Pharma Bone<br>Diseases A/S | Royalty<br>Pharma        | Yorvipath (pal<br>opegteriparatid<br>e)                                                                                              | \$150,000,000              | \$150,000,000              |
| 8/12/2024   | scPharmaceuti<br>cals Inc.              | Perceptive<br>Advisors   | FUROSCIX<br>(furosemide<br>injection)                                                                                                | \$50 million               | \$25 million               |
| 7/22/2024   | Valinor<br>Pharma                       | Grunenthal               | Movantik                                                                                                                             | \$250,000,000              | \$250,000,000              |
| 7/17/2024   | OPKO Health                             | HCRx                     | NGENLA                                                                                                                               | \$250,000,000              | \$250,000,000              |
| 7/16/2024   | Aclaris<br>Therapeutics                 | OMERS                    | OLUMIANT<br>(baricitinib)                                                                                                            | \$31,500,000               | \$26,500,000               |
| 6/28/2024   | HLS<br>Therapeutics<br>Inc.             | DRI Capital              | Xenpozyme<br>(olipudase<br>alfa)                                                                                                     | \$45,750,000               | \$13,250,000               |
| 6/27/2024   | Esperion<br>Therapeutics,<br>Inc.       | OMERS                    | Bempedoic<br>Acid Products,<br>including<br>Nilemdo®<br>(bempedoic<br>acid) and<br>Nustendi®<br>(bempedoic<br>acid and<br>ezetimibe) | \$304,656,180              | \$304,656,180              |
| 5/24/2024   | Agios Pharma<br>ceuticals               | Royalty<br>Pharma        | Vorasidenib                                                                                                                          | \$905,000,000              | \$905,000,000              |
| 5/22/2024   | Cytokinetics                            | Royalty<br>Pharma        | Omecamtiv<br>mecarbil;<br>CK-586                                                                                                     | \$400,000,000              | \$150,000,000              |
| 5/9/2024    | Verona<br>Pharma                        | OMERS                    | ensifentrine                                                                                                                         | \$250,000,000              | \$100,000,000              |
| 5/9/2024    | ImmuNext,<br>Inc.                       | Royalty<br>Pharma        | Frexalimab                                                                                                                           | \$525,000,000              | \$525,000,000              |
| 5/8/2024    | Karyopharm<br>Therapeutics<br>Inc.      | HCRx                     | XPOVIO<br>(selinexor) and<br>other future                                                                                            | \$49,494,864               | \$49,494,864               |

# GIBSON DUNN

|             |                                         |                              |                                                       |                        |                        |
|-------------|-----------------------------------------|------------------------------|-------------------------------------------------------|------------------------|------------------------|
| 4/29/2024   | Dare Bioscience                         | XOMA Royalty                 | products<br>XACIATO<br>Ovaprene;<br>Sildenafil        | \$33,000,000           | \$22,000,000           |
| 3/27/2024   | Moderna                                 | Blackstone                   | Moderna<br>influenza Flu<br>Products                  | \$750,000,000          | Undisclosed            |
| 3/4/2024    | Heidelberg Pharma                       | HCRx                         | Zircaix<br>(TLX250-CDx)                               | \$115,000,000          | \$25,000,000           |
| 2/1/2024    | Omeros                                  | DRI Capital                  | Omidria                                               | \$170,000,000          | \$115,000,000          |
| 1/17/2024   | BridgeBio Pharma                        | CPPIB and Blue Owl Capital   | Acoramidis                                            | \$500,000,000          | \$500,000,000          |
| 1/12/2024   | Talpher                                 | XOMA Royalty                 | DSUVIA                                                | \$8,000,000            | \$8,000,000            |
| <b>Date</b> | <b>Company or Seller</b>                | <b>Fund or Buyer</b>         | <b>Product Name</b>                                   | <b>Aggregate Value</b> | <b>Upfront Payment</b> |
| 12/29/2023  | ImmunityBio                             | Oberland Capital             | Anktiva (N-803)                                       | \$300,000,000          | \$200,000,000          |
| 12/15/2023  | XOMA Royalty                            | Blue Owl Capital Corporation | Vabysmo (faricimab)                                   | \$140,000,000          | \$130,000,000          |
| 11/9/2023   | Teva Pharmaceuticals International GmbH | Royalty Pharma               | Olanzapine (including TEV-447479)                     | \$125,000,000          | \$100,000,000          |
| 11/3/2023   | Xencor                                  | OMERS                        | Ultomiris (ravulizumab-cwvz)                          | \$227,000,000          | \$215,000,000          |
| 10/19/2023  | PTC Therapeutics                        | Royalty Pharma               | Monjuvi (tafasitamab-cxix)<br>Evrysdi                 | \$1,500,000,000        | \$1,000,000,000        |
| 9/5/2023    | Ascendis Pharma A/S                     | Royalty Pharma               | Skytrofa                                              | \$150,000,000          | \$150,000,000          |
| 8/24/2023   | Ferring Pharmaceuticals                 | Royalty Pharma               | Adstiladrin (nadofaragene firadenovec-vncg)           | \$500,000,000          | \$300,000,000          |
| 8/22/2023   | TheracosBio                             | HCRx                         | veterinary product (Bexacat™ (bexagliflozin tablets)) | Undisclosed            | Undisclosed            |
| 8/14/2023   | Radius Pharmaceuticals, Inc.            | DRI Capital                  | Orserdu (elacestrant)                                 | \$140,000,000          | \$130,000,000          |
| 8/2/2023    | Lantheus Holdings, Inc.                 | HCRx                         | RELISTOR (methylnaltrexone bromide)                   | \$103,000,000          | \$98,000,000           |
| 7/7/2023    | S*Bio Pte Ltd                           | DRI Capital                  | VONJO (Pacritinib)                                    | \$66,000,000           | \$66,000,000           |
| 6/30/2023   | Eisai Co., Ltd.                         | DRI Capital                  | Orserdu (elacestrant)                                 | \$85,000,000           | \$85,000,000           |
| 6/21/2023   | LadRx Corporation                       | XOMA Royalty                 | aldoxorubicin, arimoclomol                            | \$11,000,000           | \$5,000,000            |
| 6/21/2023   | Sutro Biopharma, Inc.                   | Blackstone                   | Vaxcyte Inc.'s products, including VAX-24 and VAX-31  | \$390,000,000          | \$140,000,000          |

# GIBSON DUNN

|             |                              |                      |                                                                       |                        |                        |
|-------------|------------------------------|----------------------|-----------------------------------------------------------------------|------------------------|------------------------|
| 6/5/2023    | UCLA                         | Royalty Pharma       | Erleada                                                               | \$59,000,000           | \$59,000,000           |
| 5/12/2023   | Humacyte, Inc.               | Oberland Capital     | Humacyte's Human Acellular Vessel (HAV)                               | \$150,000,000          | \$40,000,000           |
| 5/12/2023   | uniQure N.V.                 | HCRx                 | HEMGENIX                                                              | \$400,000,000          | \$375,000,000          |
| 4/27/2023   | DRI Capital                  | Sanofi               | TZIELD (tepliz umab-mzwv)                                             | \$310,000,000          | \$210,000,000          |
| 4/25/2023   | Enanta Pharmaceuticals, Inc. | OMERS                | MAVYRET (glecaprevir/pibrentasvir)/MAVIRET (glecaprevir/pibrentasvir) | \$200,000,000          | \$200,000,000          |
| 3/30/2023   | Aptevo Therapeutics Inc.     | XOMA Royalty         | IXINITY (coagulation factor IX (recombinant))                         | \$9,650,000            | \$9,600,000            |
| 3/22/2023   | PureTech                     | Royalty Pharma       | KarXT                                                                 | \$500,000,000          | \$100,000,000          |
| 3/8/2023    | MacroGenics, Inc.            | DRI Capital          | TZIELD (tepliz umab-mzwv)                                             | \$200,000,000          | \$100,000,000          |
| 1/9/2023    | Liquidia Technologies, Inc.  | HCRx                 | YUTREPIA™ (treprostinil)                                              | \$100,000,000          | \$32,500,000           |
| 1/9/2023    | Ionis Pharmaceuticals, Inc.  | Royalty Pharma       | other products marketed by Liquidia<br>SPINRAZA®<br>BIIB-115          | \$1,125,000,000        | \$500,000,000          |
|             |                              |                      | Pelacarsen                                                            |                        |                        |
| <b>Date</b> | <b>Company or Seller</b>     | <b>Fund or Buyer</b> | <b>Product Name</b>                                                   | <b>Aggregate Value</b> | <b>Upfront Payment</b> |
| 12/20/2022  | Atara Biotherapeutics        | HCRx                 | Ebvallo (tabelecleucel)                                               | \$31,000,000           | \$31,000,000           |
| 11/28/2022  | Sanofi S.A.                  | DRI Capital          | Xenpozyme (olipudase alfa)                                            | \$56,500,000           | \$30,000,000           |
| 11/9/2022   | Arrowhead Pharmaceuticals    | Royalty Pharma       | Olpasiran                                                             | \$410,000,000          | \$250,000,000          |
| 9/30/2022   | Omeros Corporation           | DRI Capital          | Omidria                                                               | \$125,000,000          | \$125,000,000          |
| 9/9/2022    | AnaptysBio, Inc.             | DRI Capital          | Zejula                                                                | \$45,000,000           | \$35,000,000           |
| 8/8/2022    | Clearside Biomedical, Inc.   | HCRx                 | XIPERE (approved), SCS Microinjector                                  | \$65,000,000           | \$32,500,000           |
| 7/21/2022   | Undisclosed                  | DRI Capital          | Pegcetacoplan including EMPAVELI®/ASPAVELI®)                          | \$24,500,000           | \$24,500,000           |
| 7/14/2022   | Ultragenyx Pharmaceuticals   | OMERS                | Crysvita                                                              | \$500,000,000          | \$500,000,000          |
| 7/13/2022   | Theravance Biopharma,        | Royalty Pharma       | TRELEGY ELLIPTA                                                       | \$1,610,000,000        | \$1,310,000,000        |

# GIBSON DUNN

|             |                                                                         |                      |                                                                                                     |                        |                        |
|-------------|-------------------------------------------------------------------------|----------------------|-----------------------------------------------------------------------------------------------------|------------------------|------------------------|
|             | Inc.<br>Innoviva, Inc.                                                  |                      | (Trelegy)                                                                                           |                        |                        |
| 6/30/2022   | Blueprint Medicines                                                     | Royalty Pharma       | ampreloxetine<br>Gavreto (pralsetinib)                                                              | \$340,000,000          | \$175,000,000          |
| 6/29/2022   | Ardelyx, Inc.                                                           | HCRx                 | tenapanor                                                                                           | \$20,000,000           | \$10,000,000           |
| 6/16/2022   | Rhythm Pharmaceuticals                                                  | HCRx                 | IMCIVREE® (s                                                                                        | \$100,000,000          | \$37,500,000           |
| 5/10/2022   | Zealand Pharma                                                          | Oberland Capital     | etmelanotide)<br>Glepaglutid; and any other products of Zealand (e.g., dasiglucagon, and BI 456906) | 15,000,000             | (60,000,000)           |
| 3/15/2022   | Eye Therapies, LLC                                                      | HCRx                 | Lumify                                                                                              | \$71,000,000           | Undisclosed            |
| 3/15/2022   | Sanofi                                                                  | Blackstone           | Sarclisa (isatuximab) (subcutaneous formulation and delivery)                                       | \$300,000,000          | N/A                    |
| 1/7/2022    | Cytokinetics Inc.                                                       | Royalty Pharma       | aficamten (royalties)                                                                               | \$150,000,000          | \$50,000,000           |
| <b>Date</b> | <b>Company or Seller</b>                                                | <b>Fund or Buyer</b> | <b>Product Name</b>                                                                                 | <b>Aggregate Value</b> | <b>Upfront Payment</b> |
| 12/31/2021  | Tafamidis Holdings, LLC (a Blackstone Life Science's portfolio company) | CPPIB                | Vyndaqel and Vyndamax (Tafamidis)                                                                   | \$221,000,000          | Undisclosed            |
| 12/13/2021  | Zealand Pharma                                                          | Oberland Capital     | Glepaglutid; and any other products of Zealand (e.g., dasiglucagon, and BI 456906)                  | \$200,000,000          | \$100,000,000          |
| 11/19/2021  | BioCryst Pharmaceuticals, Inc.                                          | Royalty Pharma       | ORLADEYO™ (berotralstat)                                                                            | \$150,000,000          | \$150,000,000          |
| 11/19/2021  | BioCryst Pharmaceuticals, Inc.                                          | OMERS                | BCX9930 ORLADEYO                                                                                    | \$150,000,000          | \$150,000,000          |
| 9/30/2021   | Galderma Laboratories, Inc.                                             | DRI Capital          | Oracea (doxycycline)                                                                                | \$46,400,000           | \$46,400,000           |
| 9/29/2021   | Spero Therapeutics                                                      | HCRx                 | Two additional undisclosed products<br>Tebipenem HBr (Tebi); and SPR720, SPR206 and any other       | \$125,000,000          | \$50,000,000           |

# GIBSON DUNN

|             |                               |                      |                                                                   |                        |                        |
|-------------|-------------------------------|----------------------|-------------------------------------------------------------------|------------------------|------------------------|
|             |                               |                      | products marketed by                                              |                        |                        |
| 8/25/2021   | CTI BioPharma Corp.           | DRI Capital          | Spero VONJO (Pacritinib)                                          | \$85,000,000           | \$60,000,000           |
| 8/25/2021   | ADC Therapeutics SA           | HCRx                 | Zynlonta (lonc astuximab tesirine), Cami (camidanluma b tesirine) | \$325,000,000          | \$225,000,000          |
| 7/15/2021   | Kuros Biosciences             | XOMA Royalty         | vidutolimod (CMP-001) (Fast Track and Orphan Drug)                | \$149,500,000          | \$7,000,000            |
| 6/23/2021   | Karyopharm Therapeutics Inc.  | HCRx                 | XPOVIO (selinexor)                                                | \$25,000,000           | \$60,000,000           |
|             |                               |                      | other Karyopharm programs, including eltanexor                    |                        |                        |
| 6/15/2021   | Inventor of Botox             | HCRx                 | Botox                                                             | \$40,000,000           | \$40,000,000           |
| 6/2/2021    | MorphoSys                     | Royalty Pharma       | Tremfya, Gant enerumab, Otilimab (Phase 3), Pelabresib, CPI-0209  | \$1,575,000,000        | \$1,425,000,000        |
| 4/8/2021    | Dicerna Pharmaceuticals, Inc. | Royalty Pharma       | OXLUMO (lumasiran)                                                | \$240,000,000          | \$180,000,000          |
| 4/1/2021    | GlaxoSmithKline (GSK)         | Royalty Pharma       | Cabometyx, Cometriq                                               | \$392,000,000          | \$342,000,000          |
| 3/30/2021   | Aptevo Therapeutics Inc.      | HCRx                 | Ruxience                                                          | \$67,500,000           | \$35,000,000           |
| 3/23/2021   | Viracta Therapeutics          | XOMA Royalty         | DAY101 (pan-RAF kinase inhibitor)                                 | \$33,500,000           | \$13,500,000           |
|             |                               |                      | vosaroxin (topoisomerase II inhibitor)                            |                        |                        |
| 2/25/2021   | Akebia Therapeutics           | HCRx                 | Vafseo (vadadustat)                                               | \$60,000,000           | \$45,000,000           |
| 2/15/2021   | Co-Inventor of Krystexxa      | HCRx                 | Krystexxa (pegloticase injection)                                 | Undisclosed            | Undisclosed            |
| 1/15/2021   | Minerva Neurosciences, Inc.   | Royalty Pharma       | Seltorexant                                                       | \$155,000,000          | \$60,000,000           |
| <b>Date</b> | <b>Company or Seller</b>      | <b>Fund or Buyer</b> | <b>Product Name</b>                                               | <b>Aggregate Value</b> | <b>Upfront Payment</b> |
| 12/22/2020  | REGENXBIO Inc.                | HCRx                 | Zolgensma                                                         | \$200,000,000          | \$200,000,000          |
| 12/16/2020  | Nektar Therapeutics           | HCRx                 | ADYNOVATE, MOVANTI,                                               | \$150,000,000          | \$150,000,000          |

# GIBSON DUNN

|           |                                              |                  |                                                                                                                                                                                                                               |               |               |
|-----------|----------------------------------------------|------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------|---------------|
|           |                                              |                  | Rebinyn, and<br>certain<br>licensed<br>products                                                                                                                                                                               |               |               |
| 12/8/2020 | Mirum Pharmaceuticals, Inc.                  | Oberland Capital | Maralixibat                                                                                                                                                                                                                   | \$200,000,000 | \$50,000,000  |
| 12/7/2020 | BioCryst Pharmaceuticals, Inc.               | Royalty Pharma   | ORLADEYO™ (berotralstat), BCX9930                                                                                                                                                                                             | \$125,000,000 | \$125,000,000 |
| 11/2/2020 | Cystic Fibrosis Foundation Therapeutics      | Royalty Pharma   | Cystic fibrosis franchise (a collection of drugs) including Kalydeco (ivacaftor), Orkambi (lumacaftor and ivacaftor), Symdeko/Symkevi (tezacaftor and ivacaftor) and Trikafta/Kaftrio (elexacaftor, tezacaftor and ivacaftor) | \$650,000,000 | \$575,000,000 |
| 11/2/2020 | Bioasis Technologies Inc.                    | XOMA Royalty     | four lysosomal storage disorder enzymes                                                                                                                                                                                       | \$1,200,000   | \$1,200,000   |
| 8/15/2020 | An inventor of VIMPAT                        | HCRx             | Vimpat (lacosamide)                                                                                                                                                                                                           | \$308,000,000 | \$308,000,000 |
| 8/7/2020  | Biohaven Pharmaceutical Holding Company Ltd. | Royalty Pharma   | zavegepant (formerly known as vazegepant; Nurtec ODT)                                                                                                                                                                         | \$250,000,000 | \$150,000,000 |
| 7/17/2020 | PTC Therapeutics, Inc.                       | Royalty Pharma   | Risdiplam                                                                                                                                                                                                                     | \$650,000,000 | \$650,000,000 |
| 6/30/2020 | Axogen, Inc.                                 | Oberland Capital | Any products, e.g., Axogen Nerve Graft                                                                                                                                                                                        | \$75,000,000  | \$35,000,000  |
| 6/12/2020 | Medtronic plc                                | Blackstone       | Various Insulin Delivery and Sensory Medical Devices (four undisclosed type 1 diabetes programs)                                                                                                                              | \$337,000,000 | N/A           |
| 6/11/2020 | Agios Pharmaceuticals, Inc.                  | Royalty Pharma   | IDHIFA (enasidenib)                                                                                                                                                                                                           | \$255,000,000 | \$255,000,000 |
| 6/10/2020 | Reata Pharmaceuticals, Inc.                  | Blackstone       | bardoxolone methyl (bardoxolone)                                                                                                                                                                                              | \$300,000,000 | \$300,000,000 |
| 6/9/2020  | AiCuris Anti-                                | Royalty          | Prevymis                                                                                                                                                                                                                      | \$220,000,000 | \$220,000,000 |

# GIBSON DUNN

|           |                                |                |                                                                    |                 |               |
|-----------|--------------------------------|----------------|--------------------------------------------------------------------|-----------------|---------------|
|           | infective CuresPharma GmbH     |                | (letermovir)                                                       |                 |               |
| 4/10/2020 | Alnylam Pharmaceuticals        | Blackstone     | Inclisiran                                                         | \$1,000,000,000 | \$500,000,000 |
| 4/7/2020  | Chiasma, Inc.                  | HCRx           | Mycapssa (octreotide) and any other future products                | \$75,000,000    | \$25,000,000  |
| 3/5/2020  | Massachusetts General Hospital | Royalty Pharma | Entyvio (vedolizumab)                                              | \$94,000,000    | \$94,000,000  |
| 2/23/2020 | RedHill Biopharma              | HCRx           | Products (any current or future products)-- e.g., Talicia, Aemcolo | \$115,000,000   | \$30,000,000  |
| 2/21/2020 | Theravance Biopharma, Inc.     | HCRx           | Trelegy Ellipta                                                    | \$200,000,000   | \$200,000,000 |

## Related Capabilities

[Royalty Finance](#)